Phase Ib Dose-Escalation Trial of Taselisib (GDC-0032) in Combination with HER2-directed Therapies in Patients with Advanced HER2+ Breast Cancer
ESMO Open(2024)
Key words
HER2,metastatic breast cancer,PIK3CA,taselisib,ctDNA
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined